Literature DB >> 15834066

Anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome.

G J Tobón, P A Correa, J-M Anaya.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15834066      PMCID： PMC1755489          DOI： 10.1136/ard.2004.029603

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

Review 1.  Autoantibodies in Sjögren's Syndrome.

Authors:  Anum Fayyaz; Biji T Kurien; R Hal Scofield
Journal:  Rheum Dis Clin North Am       Date:  2016-06-21       Impact factor: 2.670

Review 2.  Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review.

Authors:  J Avouac; L Gossec; M Dougados
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

3.  Prognostic value of Sjögren's syndrome autoantibodies.

Authors:  R Hal Scofield; Anum Fayyaz; Biji T Kurien; Kristi A Koelsch
Journal:  J Lab Precis Med       Date:  2018-10-30

4.  Diagnostic performances of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis.

Authors:  Rim Sghiri; Elyes Bouagina; Hela Zaglaoui; Hajer Mestiri; Latifa Harzallah; Imed Harrabi; Mehdi Ghannouchi; Faycel Mokhtar; Ibtissem Ghedira
Journal:  Rheumatol Int       Date:  2007-04-20       Impact factor: 2.631

5.  Joint involvement in primary Sjögren's syndrome: an ultrasound "target area approach to arthritis".

Authors:  Luis M Amezcua-Guerra; Fritz Hofmann; Angelica Vargas; Pedro Rodriguez-Henriquez; Carla Solano; Cristina Hernández-Díaz; Diana Castillo-Martinez; Lucio Ventura-Ríos; Marwin Gutiérrez; Carlos Pineda
Journal:  Biomed Res Int       Date:  2013-07-08       Impact factor: 3.411

6.  Anti-cyclic citrullinated Peptide antibody is associated with interstitial lung disease in patients with rheumatoid arthritis.

Authors:  Yufeng Yin; Di Liang; Lidan Zhao; Yang Li; Wei Liu; Yan Ren; Yongzhe Li; Xiaofeng Zeng; Fengchun Zhang; Fulin Tang; Guangliang Shan; Xuan Zhang
Journal:  PLoS One       Date:  2014-04-17       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.